Tracey L. Papenfuss, DVM, MS, PhD
Diplomate ACVP (Anatomic Pathology)
Assistant Professor, Department of Veterinary Biosciences
Phone: (614) 292-7343
The overall goal of my laboratory is to identify the factors responsible for controlling the balance between regulatory and inflammatory myeloid cells and to therapeutically modify this balance for the treatment of inflammatory disease and cancer. Induction and resolution of inflammation and immunity is largely controlled by myeloid cells, making these cells an ideal therapeutic target. My lab investigates the application of tolerogenic dendritic cells (tDCs) and myeloid derived suppressor cells (MDSCs) using a comparative and translational immunology approach. We have found that steroid hormones generate tDCs that when given to mice, protect mice from developing inflammatory autoimmune disease. We are investigating targeted induction of tDCs using novel micro particles and factors involved in tDCs differentiation. We have recently focused on the immunosuppressive tDC progenitors, MDSCs. To date, MDSC cell therapy remains relatively unexplored. Myeloid-targeted immunotherapy has broad applications in both human and veterinary medicine and much can be learned from comparative studies. My lab utilizes both mouse and dog disease models to study regulatory and inflammatory myeloid cells in disease. In combination with collaborative human model studies, we explore the impact of regulatory myeloid cells on inflammatory disease in a truly “bench to bedside” comparative and translational context.
Tracey L. Papenfuss; Assistant Professor
Zachary VanGundy: Research Assistant/Graduate Student
Cell immunotherapy (regulatory and tolerogenic myeloid cells) for the treatment of inflammatory and autoimmune disease
Dendritic cell biology; regulatory and immunogenic DCs
Modulating regulatory and immunogenic myeloid cells to impact adaptive immune responses
Myeloid derived suppressor cells in cancer and inflammation
Comparative and translational immunology
Veterinary (comparative) pathology and the use of animal models of human diseases
The following publications (listed in order of relevance to regenerative medicine) highlight both the cell immunotherapy and myeloid focus and expertise both within my laboratory and which I provide in collaborative studies. My laboratory focuses on regulatory myeloid cells and how they influence inflammation and adaptive immune responses.
Papenfuss TL, Powell ND, McClain MA, Bedarf A, Singh A, Gienapp IE, Shawler T, Whitacre CC. Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity. J Immunol. 2011 Mar 15;186(6):3346-55. Epub 2011 Feb 11. PubMed PMID: 21317386.
Papenfuss TL, Kithcart AP, Powell ND, McClain MA, Gienapp IE, Shawler TM, Whitacre CC. Disease-modifying capability of murine Flt3-ligand DCs in experimental autoimmune encephalomyelitis. J Leukoc Biol. 2007 Dec;82(6):1510-8. Epub 2007 Sep 12. PubMed PMID: 17855499.
Kithcart AP, Cox GM, Sielecki T, Short A, Pruitt J, Papenfuss T, Shawler T, Gienapp I, Satoskar AR, Whitacre CC. A small-molecule inhibitor of macrophage migration inhibitory factor for the treatment of inflammatory disease. FASEB J. 2010 Nov;24(11):4459-66. Epub 2010 Jul 12. PubMed PMID: 20624927; PubMed Central PMCID: PMC2974415.
McClain MA, Gatson NN, Powell ND, Papenfuss TL, Gienapp IE, Song F, Shawler TM, Kithcart A, Whitacre CC. Pregnancy suppresses experimental autoimmune encephalomyelitis through immunoregulatory cytokine production. J Immunol. 2007 Dec 15;179(12):8146-52. PubMed PMID: 18056357.
J. Wasserman, L. Diese, Z. VanGundy, C. London, W.E. Carson, T.L. Papenfuss Suppression of canine myeloid cells by soluble factors from cultured canine tumor cells. Veterinary Immunology and Immunopathology 2011 Dec 28. [Epub ahead of print] doi:10.1016/j.vetimm.2011.12.018
Papenfuss TL, Thrash JC, Danielson PE, Foye PE, Hllbrush BS, Sutcliffe JG, Whitacre CC, Carson MJ. Induction of Golli-MBP expression in CNS macrophages during acute LPS-induced CNS inflammation and experimental autoimmune encephalomyelitis (EAE). Scientific World Journal. 2007 Nov 2;7:112-20. PubMed PMID: 17982583; PubMed Central PMCID: PMC2626137.
Jaime-Ramirez AC, Mundy-Bosse BL, Kondadasula S, Jones NB, Roda JM, Mani A, Parihar R, Karpa V, Papenfuss TL, LaPerle KM, Biller E, Lehman A, Chaudhury AR, Jarjoura D, Burry RW, Carson WE 3rd. IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production. J Immunol. 2011 Mar 15;186(6):3401-9. Epub 2011 Feb 14. PubMed PMID: 21321106.
Park JK, Kogure T, Nuovo GJ, Jiang J, He L, Kim JH, Phelps MA, Papenfuss TL,Croce CM, Patel T, Schmittgen TD. miR-221 Silencing Blocks Hepatocellular Carcinoma and Promotes Survival. Cancer Res. 2011 Dec 15;71(24):7608-16. Epub 2011 Oct 18. PubMed PMID: 22009537.